Form 8-K Axsome Therapeutics, For: Aug 19
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Cowen Reiterates Outperform, $130 PT on Axsome Therapeutics (AXSM) Following FDA Approval
August 19, 2022 10:39 AM EDTCowen analyst Joseph Thome reiterated an Outperform rating and $130.00 price target on Axsome Therapeutics (NASDAQ: AXSM) following news that AXS-05 (Auvelity) has been approved for the treatment of MDD nearly one year after the therapy's initial PDUFA date.
The analyst... More
